| Literature DB >> 32601799 |
Jie-Ying Liang1,2, Shao-Yan Xi1,3, Qiong Shao1,4, Yun-Fei Yuan1,5, Bin-Kui Li1,5, Yun Zheng1,5, De-Shen Wang1,2, Xiao-Jun Wu1,6, Pei-Rong Ding1,6, Gong Chen1,6, Li-Ren Li1,6, Feng-Hua Wang1,2, Zhi-Qiang Wang1,2, Zhi-Zhong Pan1,6, Rui-Hua Xu7,8, Yu-Hong Li9,10.
Abstract
Various scoring systems have been proposed to predict the postoperative prognosis of colorectal liver metastasis (CRLM), including the clinical risk score (CRS), the immunoscore and so on. Recently, histopathological growth patterns (HGPs) have been recognized. However, the correlation between HGPs and the immunoscore, and their prognostic values in patients with CRLM after liver resection remain undetermined. In this study, HGPs were retrospectively evaluated in H&E-stained slides from 166 CRLM patients. The immunoscore was calculated according to the densities of immunostained CD3 + and CD8 + cells. A risk score combining HGPs, the immunoscore and the CRS was defined and divided patients into the low-, medium- and high-risk group. Our results showed that the densities of CD3 + and CD8 + cells were higher in the desmoplastic HGP (dHGP) group than in the non-dHGP group, and the proportion of high immunoscores was also higher in the dHGP group (51.9% vs. 33.0%, respectively, P = 0.020). Patients with the dHGP had significantly longer relapse-free survival (RFS) and overall survival (OS) than those with the non-HGP. The low-risk group showed significantly higher 2-year RFS and 5-year OS rates than the other two groups (RFS: 76.2%, 43.7% and 33.1%, respectively; P < 0.001; OS: 89.7%, 54.4% and 33.3%, respectively; P < 0.001). In conclusion, the dHGP correlates with relatively high immunoscores, predicting a favorable prognosis independent of the immunoscore and CRS. A novel risk score combining HGPs, the immunoscore and the CRS may be used for the stratification of CRLM patients' survival.Entities:
Keywords: Colorectal cancer liver metastasis; Histopathological growth patterns; Immunoscore
Year: 2020 PMID: 32601799 DOI: 10.1007/s00262-020-02632-6
Source DB: PubMed Journal: Cancer Immunol Immunother ISSN: 0340-7004 Impact factor: 6.968